Want to see ALKS full AI Analyst Report?
EarningsQ2 2026 Earnings Report
ALKS Q2 2026 EPS Results
Actual EPS$0.00
Consensus EPS-$0.03
Beat/MissBeat by +$0.03
One Year Ago EPS$0.67
ALKS Q2 2026 Revenue Results
Actual Revenue$496.01M
Expected Revenue$457.38M
Beat/MissBeat by +$38.63M
YoY Revenue Growth+26.97%
Earnings Announcement Details
QuarterQ2 2026
Date07/28/2026
TimeBefore Open
Conference CallTuesday, July 28, 2026
ALKS Upcoming Earnings
Alkermes's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
ALKS Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical progress, particularly across the orexin franchise and the successful integration of Avadel/LUMRYZ. Key revenue and access wins (proprietary sales +34% YoY, LYBALVI access >80%, LUMRYZ patient growth +25% YoY) and robust pipeline readouts (alixorexton LTE durability, Positive LUMRYZ Phase 3, multiple orexin programs advancing) underpin optimism. Offsetting items include margin pressure from expanding gross-to-net (LYBALVI), a substantial increase in R&D and SG&A tied to pipeline advancement and acquisition integration, a contingent consideration charge that pushes the GAAP loss guidance negative, and competitive/pricing uncertainty from other orexin entrants. Overall, the positive commercial and clinical developments outweigh the cost and near-term margin headwinds.Company Guidance
Strong Proprietary Product Sales Growth
Net sales from the proprietary product portfolio increased 34% year-over-year to $411.7M in Q2 2026, driven by psychiatry, addiction and the first full quarter contribution from LUMRYZ.
Notable Performance of Key Brands
VIVITROL Q2 net sales were $124.5M with full-year guidance of $460M–$480M; ARISTADA Q2 net sales were $96.7M with FY guidance of $365M–$385M; LYBALVI net sales grew 12% YoY to $94M (underlying TRx +18% YoY); LUMRYZ generated $96.6M in Q2 and Alkermes expects to record $315M–$335M of the LUMRYZ total FY sales of $350M–$370M.
Expanded Access for LYBALVI
LYBALVI formulary access expanded to cover >80% of insured lives (notably expanded in Part D), supporting continued prescription growth despite GTN expansion; Q2 GTN was ~36% and full-year GTN expected in the high 30s.
Orexin Pipeline Momentum and Clinical Data
Alixorexton: Phase 3 narcolepsy program enrolling on track for completion next year; Vibrance-2 and LTE interim data show sustained clinically meaningful improvements in wakefulness, cognition and fatigue up to nine months across NT1 and NT2. Vibrance-3 (IH) split-dose cohort actively enrolling with completion expected in Q4. ALKS 7290 (ADHD) Phase 1b enrolling ~50 adults with topline expected by end of Q3; ALKS 4510 (fatigue) planned to enter Phase 2 later this year with initial data expected next year.
Successful Avadel / LUMRYZ Integration
Integration of Avadel and LUMRYZ proceeded well; LUMRYZ patient base reached ~3,900 on therapy (≈25% YoY increase in patients) and net adds of ~300 QoQ, with positive Phase 3 REVITALYZ results in idiopathic hypersomnia and an sNDA planned by year-end (potential launch March 2028).
Manufacturing and Diversified Revenue Streams
Total revenues were $496M in Q2 2026, including $84.3M in manufacturing and royalty revenues (VUMERITY $30.6M, long-acting INVEGA $27.5M, CONSTA manufacturing $20.9M).
Solid Cash Position and Adjusted EBITDA
Ended Q2 with approximately $690M in cash and investments. GAAP net income was $0.5M for the quarter; Adjusted EBITDA was $139.2M (Q3 Adjusted EBITDA guidance $80M–$100M).
Commercial Durability for VIVITROL
Alkermes announced termination of the Amneal authorized generic (AG) agreement; no AG for VIVITROL in 2027 and company currently plans business assuming no generic entry in 2027 due to manufacturing complexity and limited ANDA activity.
ALKS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed